ATE506947T1 - Kondensierte thiophene verbindungen und deren verwendung zur behandlung von chronischen schmerzen - Google Patents

Kondensierte thiophene verbindungen und deren verwendung zur behandlung von chronischen schmerzen

Info

Publication number
ATE506947T1
ATE506947T1 AT02731200T AT02731200T ATE506947T1 AT E506947 T1 ATE506947 T1 AT E506947T1 AT 02731200 T AT02731200 T AT 02731200T AT 02731200 T AT02731200 T AT 02731200T AT E506947 T1 ATE506947 T1 AT E506947T1
Authority
AT
Austria
Prior art keywords
treatment
chronic pain
thiophene compounds
condensed thiophene
compounds
Prior art date
Application number
AT02731200T
Other languages
English (en)
Inventor
Allan Moorman
Romeo Romagnoli
Pier Baraldi
Original Assignee
King Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Inc filed Critical King Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE506947T1 publication Critical patent/ATE506947T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT02731200T 2001-03-30 2002-03-29 Kondensierte thiophene verbindungen und deren verwendung zur behandlung von chronischen schmerzen ATE506947T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28041601P 2001-03-30 2001-03-30
PCT/US2002/009943 WO2002083083A2 (en) 2001-03-30 2002-03-29 Pharmaceutically active compounds and methods of use

Publications (1)

Publication Number Publication Date
ATE506947T1 true ATE506947T1 (de) 2011-05-15

Family

ID=23072979

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02731200T ATE506947T1 (de) 2001-03-30 2002-03-29 Kondensierte thiophene verbindungen und deren verwendung zur behandlung von chronischen schmerzen

Country Status (15)

Country Link
US (2) US7101905B2 (de)
EP (1) EP1383463B1 (de)
JP (1) JP4303474B2 (de)
KR (1) KR100888093B1 (de)
AT (1) ATE506947T1 (de)
AU (1) AU2002303191B2 (de)
BR (1) BR0208593A (de)
CA (1) CA2443135C (de)
DE (1) DE60239864D1 (de)
ES (1) ES2365905T3 (de)
IL (2) IL158186A0 (de)
MX (1) MXPA03008936A (de)
NZ (1) NZ528635A (de)
WO (1) WO2002083083A2 (de)
ZA (1) ZA200308020B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083083A2 (en) * 2001-03-30 2002-10-24 King Pharmaceuticals, Inc. Pharmaceutically active compounds and methods of use
AR039280A1 (es) * 2002-04-11 2005-02-16 Smithkline Beecham Corp Compuesto de aminotiofeno y su uso para preparar una composicion farmaceutica
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
WO2014202765A1 (en) * 2013-06-21 2014-12-24 Lek Pharmaceuticals D.D. Preparation of chiral 1-methyl-2,3,4,5-1h-benzodiazepines via asymmetric reduction of alpha-substituted styrenes
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
CN116410205B (zh) * 2021-12-29 2024-07-05 上海皓元生物医药科技有限公司 一种3-取代-9-甲基-噻吩并三唑并噁嗪类化合物的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9401499D0 (sv) 1994-05-02 1994-05-02 Item Dev Ab New method of treatment
AU4135397A (en) 1996-09-06 1998-03-26 Takeda Chemical Industries Ltd. Condensed 4,5,6,7-tetrahydrobenzo{c}thiophenes as enhancer for cell differentiation induction factor action
US5939432A (en) 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
GB9808665D0 (en) 1998-04-23 1998-06-24 Merck Sharp & Dohme Therapeutic compounds
WO2002083083A2 (en) * 2001-03-30 2002-10-24 King Pharmaceuticals, Inc. Pharmaceutically active compounds and methods of use

Also Published As

Publication number Publication date
NZ528635A (en) 2006-11-30
EP1383463A2 (de) 2004-01-28
BR0208593A (pt) 2006-02-21
ES2365905T3 (es) 2011-10-13
IL158186A0 (en) 2004-03-28
US7449490B2 (en) 2008-11-11
WO2002083083A2 (en) 2002-10-24
US7101905B2 (en) 2006-09-05
DE60239864D1 (de) 2011-06-09
ZA200308020B (en) 2007-01-31
US20030073733A1 (en) 2003-04-17
US20060183921A1 (en) 2006-08-17
JP4303474B2 (ja) 2009-07-29
KR100888093B1 (ko) 2009-03-11
CA2443135A1 (en) 2002-10-24
CA2443135C (en) 2010-07-13
IL158186A (en) 2011-03-31
EP1383463A4 (de) 2009-03-25
WO2002083083A3 (en) 2003-11-06
AU2002303191B2 (en) 2007-01-18
JP2005500994A (ja) 2005-01-13
EP1383463B1 (de) 2011-04-27
KR20040083335A (ko) 2004-10-01
MXPA03008936A (es) 2005-03-07

Similar Documents

Publication Publication Date Title
DE60208221D1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
DE60141230D1 (de) Verwendung von Botulinum Toxin zur Behandlung von neuralgischen Schmerzen
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
EP1274444A4 (de) Arzneistoffe zur behandlung psychiatrischer oder abusus-bedingter störungen
ATE331512T1 (de) Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
DE60223694D1 (de) Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
DE60042984D1 (de) Arzneitmittel zur Behandlung von Duchenne-Muskeldystrophie
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60234760D1 (de) Phenylindole zur behandlung von hiv
DE60208186D1 (de) Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrinvermittelten erkrankungen
DE69925865D1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
ATE346614T1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
DE602004003952D1 (de) Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
ATE369130T1 (de) Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
DE60214355D1 (de) Exemestan zur behandlung von hormonabhängigen störungen
ATE522218T1 (de) Dosierungseinheit enthaltend prostaglandin-analog zur behandlung von darmverstopfung
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
ATE312104T1 (de) Verbindungen zur behandlung von beeinträchtigten fundischen entspannung
ATE506947T1 (de) Kondensierte thiophene verbindungen und deren verwendung zur behandlung von chronischen schmerzen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60223718D1 (de) Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties